Shanghai Fosun Pharmaceutical (Group) Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥41.4b (down 5.8% from FY 2022).
• Net income: CN¥2.39b (down 36% from FY 2022).
• Profit margin: 5.8% (down from 8.5% in FY 2022). The decrease in margin was driven by lower revenue.
• EPS: CN¥0.89 (down from CN¥1.43 in FY 2022).

600196 Post-Clinical Trial Products

• Approved (during full year): 20.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai Fosun Pharmaceutical (Group) Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) missed analyst estimates by 28%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are down 6.2% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Shanghai Fosun Pharmaceutical (Group).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.